Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
50-89-5
Molecular formula
C10H14N2O5
Molecular weight
242.23 g/mol
Drug class
Deoxythymidine nucleosidepyrimidine nucleoside replacement component of KYGEVVI
Mechanism of action
Supplies deoxythymidine for mitochondrial DNA nucleotide pools. In thymidine kinase 2 deficiency, the combination of deoxycytidine and deoxythymidine is intended to support mitochondrial DNA maintenance and synthesis; the individual nucleosides are administered as a fixed combination, not as separately indicated monotherapies.
Indications / reported uses
Component of the fixed combination doxecitine/doxribtimine (KYGEVVI) for treatment of thymidine kinase 2 deficiency (TK2d) in adults and paediatric patients with symptom onset on or before 12 years of age; not a stand-alone approved indication
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Doxribtimine Environmental Risk Assessment (ERA) (the Doxribtimine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.